PRLDPrelude Therapeutics IncorporatedPRLD info
$1.30info46.40%24h
Global rank23340
Market cap$54.58M
Change 7d63.11%
YTD Performance-69.56%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings-$121.83M
Dividend yield-
Main Sector
Healthcare

Prelude Therapeutics Incorporated (PRLD) Stock Overview

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma. The company is also developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 2 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

PRLD Stock Information

Symbol
PRLD
Address
200 Powder Mill RoadWilmington, DE 19803United States
Founded
-
Trading hours
9:30 AM - 4:00 PM ET
Website
https://preludetx.com
Country
πŸ‡ΊπŸ‡Έ United States
Phone Number
302 467 1280

Prelude Therapeutics Incorporated (PRLD) Price Chart

-
Value:-

Prelude Therapeutics Incorporated Overview: Key Details and Summary

Stock data
2023
Change
Price
$1.30
N/A
Market Cap
$54.58M
N/A
Shares Outstanding
41.98M
-11.38%
Employees
122.00
N/A
Earnings
2023
Change
Revenue
$0
N/A
Earnings
-$121.83M
N/A
logo
Facebook Icon
Twitter Icon
Linkedin Icon
Β© 2024 Topstocks.org